Treatment of skin disorders by topical administration of vegf inhibitors

Abstract

Topical administration of VEGF inhibitors such as, without limitation, rifamycin compounds are useful for treating skin disorders such as treating and/or reducing scars such as hypertrophic scars, and useful for treating acne and underlying acne symptoms such as skin redness.

1 . A method of reducing or preventing skin redness, eczema, or dermatitis comprising administering to a subject in need thereof a therapeutically effective amount of a formulation consisting essentially of from 1 to 5% of a rifamycin compound as the sole active ingredient in the formulation. 
     
     
         2 . A method of reducing skin redness associated with a hypertrophic scar or a method of preventing scar formation comprising administering topically to a patient in need thereof a therapeutically effective amount of a formulation consisting essentially from 1 to 5% of a vascular endothelial growth factor (VEGF) inhibitor. 
     
     
         3 . The method of  claim 2 , wherein the VEGF inhibitor is a rifamycin compound. 
     
     
         4 . The method of  claim 1  or  3 , wherein the rifamycin compound is selected from rifampicin, rifabutin, rifapentine, rifalazil, or rifaximin. 
     
     
         5 . A method of reducing hypertrophic scar or a method of preventing scar formation comprising administering topically to a patient in need thereof a therapeutically effective amount of a VEGF inhibitor, wherein the scar formation results at least in part from neovascularization. 
     
     
         6 . The method of  claim 5 , wherein the VEGF inhibitor is a rifamycin compound. 
     
     
         7 . The method of  claim 6 , wherein the rifamycin compound is rifampicin, rifabutin, rifapentine, rifalazil, or rifaximin. 
     
     
         8 . A method of treating acne, or of reducing the size of an acne, or of inhibiting neovascularization in an acne comprising administering topically to the acne of a subject in need thereof a therapeutically effective amount of a formulation consisting essentially from 1 to 5% of a rifamycin compound as the sole active ingredient in the formulation. 
     
     
         9 . The method of  claim 8  of treating acne, wherein the rifamycin compound is rifampicin, rifabutin, rifapentine, rifalazil, or rifaximin. 
     
     
         10 . The method of  claim 8  of reducing the size of an acne comprising administering topically to the acne of a subject in need thereof a therapeutically effective amount of a formulation consisting essentially from 1 to 5% of a rifamycin compound. 
     
     
         11 . The method of  claim 10 , wherein the rifamycin compound is rifampicin, rifabutin, rifapentine, rifalazil, or rifaximin. 
     
     
         12 . The method of  claim 8  of inhibiting neovascularization in an acne in a subject in need thereof, comprising administering topically to the acne in the subject a therapeutically effective amount of a formulation consisting essentially from 1 to 5% of a rifamycin compound. 
     
     
         13 . The method of  claim 12 , wherein the rifamycin compound is rifampicin, rifabutin, rifapentine, rifalazil, or rifaximin. 
     
     
         14 . The method of  claim 3 , wherein the rifamycin compound is rifampicin, rifabutin, rifapentine, rifalazil, or rifaximin. 
     
     
         15 . The method of  claim 1 , wherein the reduction or prevention of skin redness, eczema, or dermatitis is associated with acne or a hypertrophic scar. 
     
     
         16 . The method of  claim 5 , wherein the topical administration is to the area of neovascularization.